Rex Fang & Innovation Equity Premium Income ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.55 (market cap $746.48M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.61 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 3× Rex Fang & Innovation Equity Premium Income ETF's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| FEPI | SLS | |
|---|---|---|
Market Cap | $746.48M | $2.27B |
Volume | 334,337 | 4,179,659 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $15.46 |
52-Week Low | $37.98 | $1.39 |
Typical Hold Time | 56 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.59, down 0.17% on the day, with a bullish technical signal supported by moving averages. The ETF employs a covered call strategy on AI and tech mega-caps, generating weekly dividends averaging $0.20-0.21 per share. Recent news highlights its high yield but notes underperformance versus peers in total return.
Outlook: High income potential via dividends but capped upside from call-writing. Risks include concentrated tech exposure, volatility sensitivity, and competitive pressure from alternative yield strategies. Neutral sentiment prevails amid yield appeal and growth constraints.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →